AFP awarded at NPPA’s 2023 "Best Of Photojournalism Competition"
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
United Nations (AFP) | 26/01/2026 - 20:13:56 | UN welcomes last Gaza hostage remains return, urges truce implementation
Washington (AFP) | 26/01/2026 - 19:30:39 | Trump doesn't want Americans hurt but blames Democrats: White House
Bunia (AFP) | 26/01/2026 - 18:59:49 | 25 farmers killed by IS-linked rebels in DRCongo: local sources
Jerusalem (AFP) | 26/01/2026 - 18:48:46 | 'I'm proud of you my son,' father says to returned Gaza hostage's coffin
Jerusalem (AFP) | 26/01/2026 - 18:33:40 | 'We can finally say: there are no longer any hostages in Gaza': family forum
Brasília (AFP) | 26/01/2026 - 18:30:43 | Lula, Trump discuss 'Board of Peace', agree to meet in Washington: Brazil
Hamburg (AFP) | 26/01/2026 - 18:24:49 | 'Level of violence' in US 'worrying', Merz says after Minneapolis shooting
New Delhi (AFP) | 26/01/2026 - 18:13:59 | EU, India successfully conclude trade deal: Indian commerce secretary ub/msp
Gaza City (AFP) | 26/01/2026 - 18:10:10 | Gaza hospital says received nine Palestinian prisoners from Israel via Red Cross
Jerusalem (AFP) | 26/01/2026 - 17:27:44 | Israel army says kept promise to 'never leave anyone behind' with last Gaza hostage return
Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/Experian's 2026 Data Breach Industry Forecast Now ...
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose p...